All In Biotech

Drug Trial Radar · NCT06628362

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 447 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

447

Actual

Start

Nov 21, 2024

Primary completion

May 29, 2026

Study completion Oct 2, 2026

Sponsor

Lead sponsor
Carmot Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Hoffmann-La Roche
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Conditions

  • Overweight or Obese
  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • PlaceboDrug

    Placebo will be volume-matched and administered subcutaneously (SC) once weekly.

  • EnicepatideDrug

    Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Body Weight from Baseline to Week 36Time frame: Baseline to Week 36
  2. Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36Time frame: Baseline to Week 36

Locations

70 sites in 6 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Yuma Clinical Trials

    Yuma, Arizona

  • AMCR Institute

    Escondido, California

  • Ark Clinical-Fountain Valley

    Fountain Valley, California

  • Orange Country Research Center

    Lake Forest, California

  • Ark Clinical Research

    Long Beach, California

  • Catalina Research Institute, LLC

    Montclair, California

  • Asclepes Research Centers

    Sherman Oaks, California

  • Encompass Clinical Research

    Spring Valley, California

  • Flourish Research - Boca Raton

    Boca Raton, Florida

  • Tampa Bay Medical Research

    Clearwater, Florida

  • K2 Medical Research, LLC - Maitland

    Maitland, Florida

  • K2 Medical Research, LLC - Orlando

    Maitland, Florida

  • Flourish Research Acquisition, LLC

    Miami, Florida

  • K2 Medical Research, LLC - South Orlando

    Orlando, Florida

  • Aging Well Associates

    St. Petersburg, Florida

  • K2 Medical Research Tampa

    Tampa, Florida

  • K2 Summit Research

    The Villages, Florida

  • Privia Medical Group Georgia, LLC

    Fayetteville, Georgia

  • Privia Medical Group Georgia - Thomasville

    Thomasville, Georgia

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia

  • Duly Health and Care

    Lombard, Illinois

  • McFarland Clinic

    Ames, Iowa

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas

  • NOLA Cares, LLC

    Metairie, Louisiana

  • Flourish Research Acquisition, LLC dba Flourish Bowie

    Bowie, Maryland

  • Centennial Medical Group

    Elkridge, Maryland

  • NECCR PrimaCare Research LLC

    Fall River, Massachusetts

  • Olive Branch Family Medical Center; Family Medicine

    Olive Branch, Mississippi

  • SKY Integrative Medical Center/SKYCRNG

    Ridgeland, Mississippi

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Ellipsis Research Group

    Brooklyn, New York

  • Accellacare of Cary

    Cary, North Carolina

  • Accellacare - Hickory

    Hickory, North Carolina

  • Accellacare of Rocky Mount

    Rocky Mount, North Carolina

  • Accellacare of Piedmont Healthcare

    Statesville, North Carolina

  • Accellacare of Wilmington, LLC

    Wilmington, North Carolina

  • Accellacare Research of Winston Salem

    Winston-Salem, North Carolina

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.